NCT00785538 - A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL

IMC-A12

"Cohort 1~3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period."

BIOLOGICAL

IMC-A12

"Cohort 2~6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."

BIOLOGICAL

IMC-A12

"Cohort 3~10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."

BIOLOGICAL

IMC-A12

"Cohort 4~15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."

BIOLOGICAL

IMC-A12

"Cohort 5~21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."

BIOLOGICAL

IMC-A12

"Cohort 6~27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."

Trial Locations (3)

ImClone Investigational Site, Detroit

ImClone Investigational Site, Scottsdale

ImClone Investigational Site, Seattle

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY